Developing rationally designed orally delivered enzyme therapeutics for diseases caused by malabsorption syndromes and nutrient metabolism disorders.
Framingham, MA
Joined March 2023
- Tweets8
- Following35
- Followers14
- Likes0
Anagram Therapeutics Completes Dosing Study of ANG003, a Broad-Spectrum Oral Enzyme Replacement Therapy, in People with Cystic Fibrosis
shorturl.at/5nuPE
@CF_Foundation @NatPancFdn
Anagram Therapeutics is thrilled to announce Expansion of Joint Product Development Collaboration with ATUM to Accelerate Development of Orally Delivered Enzymes for Malabsorption and Nutrient Metabolism Disorders
tinyurl.com/58mcj9kk
Anagram Therapeutics Announces Initiation of Clinical Study of ANG003 in People with Cystic Fibrosis
tinyurl.com/58mcj9kk
Anagram welcomes Hugh, Pam and Sophia! What a great set of expertise to add to the Team! #anagramtx
anagramtx.com/news
Extremely grateful to the @CF_Foundation for their ongoing support to accelerate ANG003.
on.cff.org/40Mhaoc
